150 related articles for article (PubMed ID: 36358082)
41. In vitro characterization and growth inhibition effect of nanostructured lipid carriers for controlled delivery of methotrexate.
Abdelbary G; Haider M
Pharm Dev Technol; 2013; 18(5):1159-68. PubMed ID: 21958084
[TBL] [Abstract][Full Text] [Related]
42. Nanostructured Lipid Carriers for Oral Bioavailability Enhancement of Exemestane: Formulation Design, In Vitro, Ex Vivo, and In Vivo Studies.
Singh A; Neupane YR; Mangla B; Kohli K
J Pharm Sci; 2019 Oct; 108(10):3382-3395. PubMed ID: 31201904
[TBL] [Abstract][Full Text] [Related]
43. RIPL peptide-conjugated nanostructured lipid carriers for enhanced intracellular drug delivery to hepsin-expressing cancer cells.
Lee SG; Kim CH; Sung SW; Lee ES; Goh MS; Yoon HY; Kang MJ; Lee S; Choi YW
Int J Nanomedicine; 2018; 13():3263-3278. PubMed ID: 29910614
[TBL] [Abstract][Full Text] [Related]
44. Lipids-based nanostructured lipid carriers (NLCs) for improved oral bioavailability of sirolimus.
Yu Q; Hu X; Ma Y; Xie Y; Lu Y; Qi J; Xiang L; Li F; Wu W
Drug Deliv; 2016 May; 23(4):1469-75. PubMed ID: 27187522
[TBL] [Abstract][Full Text] [Related]
45. Formulation optimization, in vitro and in vivo evaluation of agomelatine-loaded nanostructured lipid carriers for augmented antidepressant effects.
Gul M; Shah FA; Sahar NU; Malik I; Din FU; Khan SA; Aman W; Choi HI; Lim CW; Noh HY; Noh JS; Zeb A; Kim JK
Colloids Surf B Biointerfaces; 2022 Aug; 216():112537. PubMed ID: 35561634
[TBL] [Abstract][Full Text] [Related]
46. Lactoferrin-loaded nanostructured lipid carriers (NLCs) as a new formulation for optimized ocular drug delivery.
Varela-Fernández R; García-Otero X; Díaz-Tomé V; Regueiro U; López-López M; González-Barcia M; Isabel Lema M; Javier Otero-Espinar F
Eur J Pharm Biopharm; 2022 Mar; 172():144-156. PubMed ID: 35183717
[TBL] [Abstract][Full Text] [Related]
47. Physicochemical properties of nevirapine-loaded solid lipid nanoparticles and nanostructured lipid carriers.
Kuo YC; Chung JF
Colloids Surf B Biointerfaces; 2011 Apr; 83(2):299-306. PubMed ID: 21194902
[TBL] [Abstract][Full Text] [Related]
48. Nanostructured lipid carriers (NLCs) for drug delivery and targeting.
Fang CL; Al-Suwayeh SA; Fang JY
Recent Pat Nanotechnol; 2013 Jan; 7(1):41-55. PubMed ID: 22946628
[TBL] [Abstract][Full Text] [Related]
49. Preparation of Chitosan-Coated Nanostructured Lipid Carriers (CH-NLCs) to Control Iron Delivery and Their Potential Application to Food Beverage System.
Lee SA; Joung HJ; Park HJ; Shin GH
J Food Sci; 2017 Apr; 82(4):904-912. PubMed ID: 28241098
[TBL] [Abstract][Full Text] [Related]
50. Development of nanostructured lipid carriers as a promising tool for methotrexate delivery: physicochemical and
Rathee J; Kanwar R; Kumari L; Pawar SV; Sharma S; Ali ME; Salunke DB; Mehta SK
J Biomol Struct Dyn; 2023 Apr; 41(7):2747-2758. PubMed ID: 35238266
[TBL] [Abstract][Full Text] [Related]
51. Submicron complex lipid carriers for curcumin delivery to intestinal epithelial cells: Effect of different emulsifiers on bioaccessibility and cell uptake.
Yucel C; Quagliariello V; Iaffaioli RV; Ferrari G; Donsì F
Int J Pharm; 2015 Oct; 494(1):357-69. PubMed ID: 26291881
[TBL] [Abstract][Full Text] [Related]
52. Rifampicin loaded mannosylated cationic nanostructured lipid carriers for alveolar macrophage-specific delivery.
Song X; Lin Q; Guo L; Fu Y; Han J; Ke H; Sun X; Gong T; Zhang Z
Pharm Res; 2015 May; 32(5):1741-51. PubMed ID: 25407545
[TBL] [Abstract][Full Text] [Related]
53. Box-Behnken study design for optimization of bicalutamide-loaded nanostructured lipid carrier: stability assessment.
Kudarha R; Dhas NL; Pandey A; Belgamwar VS; Ige PP
Pharm Dev Technol; 2015; 20(5):608-18. PubMed ID: 24785784
[TBL] [Abstract][Full Text] [Related]
54. Development, in vitro and in vivo evaluation of miltefosine loaded nanostructured lipid carriers for the treatment of Cutaneous Leishmaniasis.
Khan AS; Ud Din F; Ali Z; Bibi M; Zahid F; Zeb A; Mujeeb-Ur-Rehman ; Khan GM
Int J Pharm; 2021 Jan; 593():120109. PubMed ID: 33253802
[TBL] [Abstract][Full Text] [Related]
55. Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy?
Qu J; Zhang L; Chen Z; Mao G; Gao Z; Lai X; Zhu X; Zhu J
Drug Deliv; 2016 Nov; 23(9):3408-3416. PubMed ID: 27181462
[TBL] [Abstract][Full Text] [Related]
56. Chitosan coated nanostructured lipid carriers (NLCs) for loading Vitamin D: A physical stability study.
Rabelo RS; Oliveira IF; da Silva VM; Prata AS; Hubinger MD
Int J Biol Macromol; 2018 Nov; 119():902-912. PubMed ID: 30063935
[TBL] [Abstract][Full Text] [Related]
57. Process, optimization, and characterization of budesonide-loaded nanostructured lipid carriers for the treatment of inflammatory bowel disease.
Sinhmar GK; Shah NN; Chokshi NV; Khatri HN; Patel MM
Drug Dev Ind Pharm; 2018 Jul; 44(7):1078-1089. PubMed ID: 29376433
[TBL] [Abstract][Full Text] [Related]
58. Preparation of Ergosterol-Loaded Nanostructured Lipid Carriers for Enhancing Oral Bioavailability and Antidiabetic Nephropathy Effects.
Dong Z; Iqbal S; Zhao Z
AAPS PharmSciTech; 2020 Jan; 21(2):64. PubMed ID: 31932990
[TBL] [Abstract][Full Text] [Related]
59. A Detailed Insight into Nanostructured Lipid Carriers: A Versatile Drug Delivery System.
Ghosh S; Tiwari T; Nagaich U; Jain N
Recent Pat Nanotechnol; 2023; 17(4):284-306. PubMed ID: 35616677
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of the in vitro differential protein adsorption patterns of didanosine-loaded nanostructured lipid carriers (NLCs) for potential targeting to the brain.
Kasongo KW; Jansch M; Müller RH; Walker RB
J Liposome Res; 2011 Sep; 21(3):245-54. PubMed ID: 21174528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
